Avacta announced the BAMS™ assay to detect the SARS-CoV-2 virus has been launched as a research kit1 by its partner Adeptrix and the assay has been presented by Bruker Scientific, a mass spectrometer manufacturer, in a new application note.
The bead-assisted mass spectrometry (BAMS) assay uses the Affimer reagents specific to the SARS-CoV-2 virus to capture the virus spike protein from the sample for rapid detection by mass spectrometry, using the installed base of these instruments in hospitals. Up to one thousand samples per day can be analysed by a single technician using BAMS, making BAMS a very attractive high throughput technique for COVID-19 diagnosis and research.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox! Sign up now!
Adeptrix has launched a BAMS research assay kit incorporating Avacta’s Affimer reagents in order to make this tool available to researchers globally to support the fight against the coronavirus. Work carried out in parallel by Bruker to assess the performance of the assay has been published by Bruker in a detailed application note.